ATE131063T1 - Behandlung von fettleibigkeit mit einem alpha-2- adrenergen-agonisten und einem wachstumshormon freigebenden peptid. - Google Patents

Behandlung von fettleibigkeit mit einem alpha-2- adrenergen-agonisten und einem wachstumshormon freigebenden peptid.

Info

Publication number
ATE131063T1
ATE131063T1 AT91914999T AT91914999T ATE131063T1 AT E131063 T1 ATE131063 T1 AT E131063T1 AT 91914999 T AT91914999 T AT 91914999T AT 91914999 T AT91914999 T AT 91914999T AT E131063 T1 ATE131063 T1 AT E131063T1
Authority
AT
Austria
Prior art keywords
growth hormone
alpha
adrenergic agonist
obesity
treatment
Prior art date
Application number
AT91914999T
Other languages
English (en)
Inventor
Jesus Devesa Chalet As Mugica
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE131063T1 publication Critical patent/ATE131063T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT91914999T 1990-09-10 1991-09-06 Behandlung von fettleibigkeit mit einem alpha-2- adrenergen-agonisten und einem wachstumshormon freigebenden peptid. ATE131063T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/580,686 US5120713A (en) 1990-09-10 1990-09-10 Treatment of obesity with an alpha-2-adrenergic agonist and a growth hormone releasing peptide

Publications (1)

Publication Number Publication Date
ATE131063T1 true ATE131063T1 (de) 1995-12-15

Family

ID=24322121

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91914999T ATE131063T1 (de) 1990-09-10 1991-09-06 Behandlung von fettleibigkeit mit einem alpha-2- adrenergen-agonisten und einem wachstumshormon freigebenden peptid.

Country Status (11)

Country Link
US (1) US5120713A (de)
EP (1) EP0500847B1 (de)
JP (1) JP3255289B2 (de)
AT (1) ATE131063T1 (de)
AU (1) AU650048B2 (de)
CA (1) CA2072624C (de)
DE (1) DE69115247T2 (de)
DK (1) DK0500847T3 (de)
ES (1) ES2080331T3 (de)
GR (1) GR3018922T3 (de)
WO (1) WO1992004040A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5428013A (en) * 1991-01-04 1995-06-27 Mugica; Jesus D. Differential diagnosis and treatment of the states of growth hormone insufficiency (or deficiency) with an alpha-2-adrenergic agonist and a growth hormone releasing peptide
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US7077822B1 (en) 1994-02-09 2006-07-18 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US6129685A (en) * 1994-02-09 2000-10-10 The University Of Iowa Research Foundation Stereotactic hypothalamic obesity probe
US5605886A (en) * 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US6696063B1 (en) * 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
US6231594B1 (en) 1999-08-11 2001-05-15 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DK1355644T3 (da) * 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
US20020183305A1 (en) * 2001-01-26 2002-12-05 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
PL364178A1 (en) * 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US6582457B2 (en) * 2001-02-15 2003-06-24 Radiant Medical, Inc. Method of controlling body temperature while reducing shivering
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
US7655658B2 (en) * 2001-08-10 2010-02-02 Palatin Technologies, Inc. Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
AU2002331064B2 (en) * 2001-08-10 2007-08-23 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7456184B2 (en) * 2003-05-01 2008-11-25 Palatin Technologies Inc. Melanocortin receptor-specific compounds
US7354923B2 (en) * 2001-08-10 2008-04-08 Palatin Technologies, Inc. Piperazine melanocortin-specific compounds
US7732451B2 (en) * 2001-08-10 2010-06-08 Palatin Technologies, Inc. Naphthalene-containing melanocortin receptor-specific small molecule
US7718802B2 (en) 2001-08-10 2010-05-18 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7727990B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine and keto-piperazine compounds
US7968548B2 (en) 2003-05-01 2011-06-28 Palatin Technologies, Inc. Melanocortin receptor-specific piperazine compounds with diamine groups
US7727991B2 (en) 2003-05-01 2010-06-01 Palatin Technologies, Inc. Substituted melanocortin receptor-specific single acyl piperazine compounds
EP1680189A2 (de) * 2003-11-05 2006-07-19 Schering Corporation Kombinationen von lipidmodulierenden mitteln mit substituierten azetidinonen zur behandlung von vaskularen erkrankungen
US7709484B1 (en) 2004-04-19 2010-05-04 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US7834017B2 (en) 2006-08-11 2010-11-16 Palatin Technologies, Inc. Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
KR20100056523A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 ｇｒｆ-1 (1-29) 및 코르티코트로핀-방출 인자의 용도
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224316A (en) * 1979-03-30 1980-09-23 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
IT1191611B (it) * 1985-05-15 1988-03-23 Eugenio E Muller Formalazioni farmaceutiche per stimolare la liberazione di ormone somatotropo
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative

Also Published As

Publication number Publication date
DK0500847T3 (da) 1996-01-08
JPH05503710A (ja) 1993-06-17
EP0500847A1 (de) 1992-09-02
DE69115247D1 (de) 1996-01-18
JP3255289B2 (ja) 2002-02-12
AU650048B2 (en) 1994-06-09
ES2080331T3 (es) 1996-02-01
US5120713A (en) 1992-06-09
GR3018922T3 (en) 1996-05-31
CA2072624A1 (en) 1992-03-11
DE69115247T2 (de) 1996-07-25
AU8430591A (en) 1992-03-30
CA2072624C (en) 1999-03-23
WO1992004040A1 (en) 1992-03-19
EP0500847B1 (de) 1995-12-06

Similar Documents

Publication Publication Date Title
ATE131063T1 (de) Behandlung von fettleibigkeit mit einem alpha-2- adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
DE68919358D1 (de) Zusammensetzung zur behandlung der schizophrenie.
DE69012261D1 (de) Verwendung von Sertralin zur Behandlung verfrühter Ejakulation.
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
ATE240723T1 (de) Transdermale therapeutische vorrichtung mit capsaicin und seinen analogen
ATE100714T1 (de) Arzneimittel (calcitoningen verwandte peptide) zur behandlung erektiler dysfunktionen.
RU93054017A (ru) Способ лечения остеопороза, композиция для лечения остеопороза, применение активно действующего на кости фосфоната и эстрогенного гормона для лечения остеопороза
ATE144149T1 (de) Therapeutisches verfahren zur behandlung von iddm
DE69800859D1 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
KR960000921A (ko) 칼시토닌 유도체 및 그 용도
ES2025107B3 (es) Vendaje para el tratamiento de dolencias en el antebrazo
DE69230287D1 (de) Verbindungen und pharmazeutische zusammensetzungen zum nachweis und zur lokalisierung von geweben mit neurokinin-1-rezeptoren
ATE63316T1 (de) Verwendung von n, n'-bis-l-aminosaeure-lcystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
ATE141512T1 (de) Verfahren zur behandlung von unfruchtbarkeit und dafür verwendbares mittel
WO2003092619A3 (en) Prevention and treatment of type 2 diabetes
DE60015135D1 (de) Prolaktin freisetzendes peptid und verwendung zur behandlung von schmerzen
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
ES2168772T3 (es) Uso de hormona del crecimiento en composiciones para el tratamiento de la resistencia del corazon a la insulina.
CY1108368T1 (el) Διαδερμικη συσκευη φελοδιπινης και μεθοδοι
RU96103577A (ru) Способ лечения саркомы капоши
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
DE3776662D1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
RU2001124669A (ru) Способ профилактики паратифа телят

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee